Literature DB >> 131202

Increased prolactin levels during reserpine treatment of hypertensive patients.

P A Lee, M R Kelly, J D Wallin.   

Abstract

Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P less than .005). This association between regular, long-term reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 131202

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Adverse effects of antihypertensive drugs.

Authors:  F E Husserl; F H Messerli
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

3.  Prolactin secretion during reserpine and syrosingopine treatment.

Authors:  E Camanni; E Strumia; P Portaleone; G M Molinatti
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 4.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

Review 5.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Reserpine, hydrochlorothiazide and pituitary-gonadal hormones in hypertensive patients.

Authors:  T W Boyden; C A Nugent; T Ogihara; T Maeda
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

7.  Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women.

Authors:  P S Bhathal; R W Brown; G C Lesueur; I S Russell
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.